Abbott Laboratories Stock vs Competition: Who Wins?
Abbott Laboratories’ stock has mostly underperformed peers over the past year (12M return of -0.11). However, a deeper look as of 1/26/2026 reveals a relatively attractive valuation with a significantly lower PE ratio (13.56) versus its group. While its LTM revenue growth (0.0637) is solid compared to many competitors, profitability, with LTM operating margin (0.1759) and FCF margin (0.1578), generally lags top performers like JNJ. Still, its consistent cash generation offers a stable foundation.
- ABT’s 17.6% operating margin, lowest among peers, suggests its diversified medtech/diagnostics mix contrasts JNJ’s higher 26.2% due to pharma strength.
- ABT’s 6.4% revenue growth, exceeding peers like JNJ, MDT, TMO, DHR, reflects medtech strength, yet trails BSX’s new product-driven market gains.
- ABT’s stock is down 11.4%, underperforming peers due to Q4 2024 revenue miss and diagnostics softness; its 13.6 PE signals valuation concerns.
Here’s how Abbott Laboratories stacks up across size, valuation, and profitability versus key peers.
| ABT | JNJ | MDT | TMO | DHR | BSX | |
|---|---|---|---|---|---|---|
| Market Cap ($ Bil) | 189.5 | 533.4 | 129.1 | 236.9 | 168.2 | 138.6 |
| Revenue ($ Bil) | 43.8 | 92.1 | 34.8 | 43.7 | 24.3 | 19.4 |
| PE Ratio | 13.6 | 21.2 | 27.1 | 36.1 | 48.0 | 49.6 |
| LTM Revenue Growth | 6.4% | 5.1% | 5.3% | 3.2% | 2.2% | 21.6% |
| LTM Operating Margin | 17.6% | 26.2% | 19.3% | 18.4% | 19.0% | 19.2% |
| LTM FCF Margin | 15.8% | 20.3% | 15.0% | 14.0% | 20.7% | 18.7% |
| 12M Market Return | -11.4% | 55.5% | 15.1% | 9.4% | -3.1% | -8.2% |
For more details on Abbott Laboratories, read Buy or Sell ABT Stock. Below we compare ABT’s growth, margin, and valuation with peers across years
Revenue Growth Comparison
- Abbott Laboratories Stock: Join the Rally at a 19% Discount
- Pay Less, Gain More: RMD Tops Abbott Laboratories Stock
- Buy or Sell Abbott Laboratories Stock?
- Is Abbott Laboratories Stock Built to Withstand More Downside?
- How Did Abbott Fare In Q4 And What Lies Ahead?
- Pay Less, Gain More: RMD Tops Abbott Laboratories Stock
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| ABT | 6.4% | – | 4.6% | -8.1% | 1.3% |
| JNJ | 5.1% | – | 4.3% | 6.5% | 1.6% |
| MDT | 5.3% | 3.6% | 3.6% | -1.4% | |
| TMO | 3.2% | – | 0.1% | -4.6% | 14.5% |
| DHR | 2.2% | – | -0.1% | -10.3% | 7.4% |
| BSX | 21.6% | – | 17.6% | 12.3% | 6.7% |
Operating Margin Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| ABT | 17.6% | – | 16.3% | 16.2% | 19.2% |
| JNJ | 26.2% | – | 24.9% | 27.5% | 26.3% |
| MDT | 19.3% | 19.5% | 17.1% | 18.7% | |
| TMO | 18.4% | – | 18.0% | 17.1% | 18.9% |
| DHR | 19.0% | – | 20.4% | 21.8% | 28.3% |
| BSX | 19.2% | – | 17.9% | 17.0% | 16.0% |
PE Ratio Comparison
| LTM | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|
| ABT | 13.6 | – | 16.3 | 34.4 | 27.8 |
| JNJ | 21.2 | – | 35.4 | 10.4 | 22.9 |
| MDT | 27.1 | 26.5 | 28.9 | 29.2 | |
| TMO | 36.1 | – | 34.9 | 33.5 | 29.9 |
| DHR | 48.0 | – | 42.9 | 35.5 | 23.3 |
| BSX | 49.6 | – | 75.7 | 81.5 | 118.5 |
Still not sure about ABT stock? Consider portfolio approach.
Portfolios Win When Stock Picks Fall Short
Individual stocks can soar or tank but one thing matters: staying invested. The right portfolio can help you stay invested, capture upside and mitigate the downside associated with any individual stock.
The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.